# One Infusion to Rewrite a Cholesterol Gene: What the VERVE-102 Base-Editing Trial Means for Patients In a new phase 1 clinical trial, researchers tested VERVE-102, a one-time investigational gene-editing therapy designed to permanently lower LDL ("bad") cholesterol by inactivating the PCSK9 gene in the liver. Among 35 adults with inherited or premature heart disease risk, a single intravenous infusion produced dose-dependent reductions in blood PCSK9 protein (up to 88% at the highest dose) and LDL cholesterol (up to 62%, an absolute drop of 78 mg/dL). Side effects were mostly mild-to-moderate infusion reactions and temporary liver enzyme elevations, with no dose-limiting toxic effects or deaths, and the cholesterol-lowering effects appeared durable for a year or more. # One Infusion to Rewrite a Cholesterol Gene: What the VERVE-102 Base-Editing Trial Means for Patients ## Table of Contents - Key Points - Why This Research Matters: The Problem of Daily Cholesterol Treatment - What Is VERVE-102 and How Does Base Editing Work? - How the Study Was Designed (Methods) - Who Took Part in the Study - Safety Results: What Side Effects Occurred - Key Findings: Reductions in PCSK9 and LDL Cholesterol - How Long Did the Effects Last? - Exploring the Dose Response - What This Means for Patients (Clinical Implications) - Study Limitations: What This Trial Could Not Prove - Recommendations for Patients Now - Frequently Asked Questions - Source Information ## Key Points - In a phase 1 trial of 35 adults with familial hypercholesterolemia or premature coronary disease, one VERVE-102 infusion lowered LDL by up to 62% at the highest dose. - Blood PCSK9 protein fell by up to 88% on average, and effects appeared durable in participants followed for up to 18 months. - No dose-limiting toxic effects or deaths occurred; side effects were mostly mild-to-moderate infusion reactions and temporary liver enzyme elevations. - The trial was open-label with no control group and measured cholesterol levels, not heart attacks or strokes; larger, longer studies are needed. - VERVE-102 is investigational and unapproved; patients should continue prescribed statins, ezetimibe, or PCSK9 inhibitor therapy and discuss LDL targets with their doctor. ## Why This Research Matters: The Problem of Daily Cholesterol Treatment The story of this therapy begins with a remarkable genetic finding from about twenty years ago. Researchers discovered that some people carry naturally occurring "loss-of-function" variants in a gene called PCSK9 (proprotein convertase subtilisin–kexin type 9). These variants reduce the gene's activity, giving these individuals lifelong low levels of PCSK9 protein and low LDL cholesterol. Even more striking, those people experience far fewer heart attacks and strokes, with no apparent adverse health effects. Since that discovery, PCSK9 has become one of the most validated targets in cardiovascular medicine, and multiple therapies that block it have been approved. Several large cardiovascular-outcome studies have confirmed the safety and effectiveness of PCSK9 inhibition in patients with high cholesterol. The key question has always been **timing**. Studies using a method called Mendelian randomization show that the heart-protective benefit depends not only on how much LDL cholesterol drops, but on how long a person lives with lower levels. For example, lowering LDL by 39 mg per deciliter (1.0 mmol per liter) over a 5-year period with statin treatment reduces the risk of major vascular events by approximately 22%. Yet people who carry PCSK9 gene variants producing the same lifelong reduction have up to an **88% lower lifetime risk of coronary artery disease events**. In other words, the benefits of lowering cholesterol build up over many years. Today's treatment model relies on daily pills or regular injections, and it often fails in the real world. Factors such as inconsistent access to care, side effects, and out-of-pocket costs drive a high rate of treatment discontinuation. Across all classes of lipid-lowering therapy — including PCSK9 inhibitor injections — the real-world rate of stopping treatment ranges from **30% to 50% within 12 months** of starting. This lack of treatment persistence is linked to worsened cardiovascular outcomes. For high-risk patients — those with heterozygous familial hypercholesterolemia (an inherited condition causing very high cholesterol from birth) or premature coronary artery disease — guidelines recommend lowering LDL over decades. VERVE-102 was designed to change that model: one infusion that permanently edits the PCSK9 gene in the liver, mimicking the protective natural variants and durably lowering LDL cholesterol after a single dose. ## What Is VERVE-102 and How Does Base Editing Work? VERVE-102 is an investigational "in vivo" (inside the body) base-editing medicine. Rather than cutting the DNA in two pieces the way some older gene-editing approaches do, base editing makes a single, tiny chemical change — like changing one letter in a very long book. This precision reduces the risk of unintended damage. The therapy contains two drug components packaged together in a fatty delivery particle called a lipid nanoparticle: - A messenger RNA (mRNA) that carries the instructions for making an **adenine base-editor protein** (version 8.8) - A **guide RNA** that directs the editor to the exact right spot in the PCSK9 gene The delivery particle is coated with a sugar molecule called N-acetylgalactosamine (GalNAc). This sugar acts like a key that helps the particle enter liver cells (hepatocytes) through the asialoglycoprotein receptor, supplementing the usual apolipoprotein E–mediated uptake through the LDL receptor. Once inside the cell, the mRNA is translated into the base-editor protein, which pairs with the guide RNA. Together they travel to the nucleus and find their target: a splice site at the 5′ end of intron 1 of the PCSK9 gene. Here is the molecular sequence of events, step by step: 1. The DNA strands separate to form an "R-loop" structure at the target site. 1. An engineered adenosine deaminase enzyme chemically converts an adenosine base to inosine. 1. The editor nicks (cuts one strand of) the opposite strand of DNA using a modified CRISPR-Cas9 domain that has been catalytically inactivated so it does not make a double-strand break. 1. During DNA repair, the inosine is read as guanosine, and a cytidine is placed on the repaired strand. 1. The result is a single A·T to G·C base-pair substitution. 1. This tiny change alters the splice site, causing read-through to a stop codon (TAG), which prevents the PCSK9 protein from ever being made in the liver. The result: lower levels of PCSK9 protein in the blood, which means the liver keeps more LDL receptors on its surface to clear LDL cholesterol from the bloodstream. Preclinical safety data were reassuring. In off-target screening experiments in primary human liver cells grown in the lab, editing with VERVE-102 was specific for the intended PCSK9 site. In nonhuman primates receiving the infusion, mapping of editing activity across 26 tissues showed high levels of editing in the liver and low levels in the adrenal glands and spleen. Studies in mice given an equivalent therapy targeting the mouse Pcsk9 gene showed no transmission of the edit to offspring, meaning there was no evidence of editing in sperm or egg cells (the germline). ## How the Study Was Designed (Methods) This was a **phase 1, open-label, single-ascending-dose study**, known as Heart-2. "Open-label" means both researchers and participants knew which treatment was given (there was no placebo group). The study is ongoing and this report is an interim analysis. **Who was eligible:** Adults aged 18 to 70 with either a diagnosis of heterozygous familial hypercholesterolemia (an inherited condition causing very high LDL) or premature coronary artery disease (defined as heart disease occurring at age 55 or younger in men, or 65 or younger in women). Participants needed a fasting LDL cholesterol level of at least 70 mg per deciliter (1.8 mmol per liter) while taking the maximum tolerated dose of oral lipid-lowering therapy (a statin, with or without ezetimibe). People with uncontrolled high blood pressure, inadequately controlled type 2 diabetes, or ongoing use of a PCSK9 inhibitor were excluded. **How treatment was given:** Each participant received a single intravenous infusion of VERVE-102 over up to roughly 4 hours, at one of six weight-based doses: - 0.3 mg of total RNA per kilogram of body weight - 0.45 mg per kilogram - 0.6 mg per kilogram - 0.7 mg per kilogram - 0.8 mg per kilogram - 1.0 mg per kilogram All participants received premedication to reduce the risk of infusion-related reactions. This consisted of dexamethasone (a steroid) on the day before the infusion, and dexamethasone plus a histamine H1-receptor antagonist and a histamine H2-receptor antagonist on the day of the infusion. Participants stayed in the hospital for observation for at least 2 days and had daily clinical and laboratory assessments through day 4. **Follow-up schedule:** After the inpatient period, follow-up visits occurred weekly through day 28, then on days 60, 90, 180, 270, and 365. The study plans to enroll up to 85 participants in total to characterize the therapy across dose levels. Participants who complete their day-365 visit are expected to transition to a long-term follow-up study. **What was measured:** The primary objective was safety. Adverse events were graded using the Common Terminology Criteria for Adverse Events, version 5.0. Secondary objectives included measuring how the drug moves through the body (pharmacokinetics) and its biological effects (pharmacodynamics), measured as the percentage change and absolute change from baseline in plasma PCSK9 and fasting LDL cholesterol levels. Oversight was provided by a study monitoring committee and an independent data and safety monitoring board, which reviewed data before each dose escalation. The study was funded by Verve Therapeutics (a wholly owned subsidiary of Eli Lilly) and conducted at sites in Australia, Canada, New Zealand, and the United Kingdom, in accordance with the Declaration of Helsinki and international Good Clinical Practice standards. The data cutoff date for this interim analysis was February 27, 2026. No formal statistical testing was performed; results are descriptive. ## Who Took Part in the Study A total of **35 participants** had received VERVE-102 and completed at least 28 days of follow-up at the time of this analysis. The number of participants per dose group was: - 4 participants at 0.3 mg per kilogram - 6 participants at 0.45 mg per kilogram - 4 participants at 0.6 mg per kilogram - 8 participants at 0.7 mg per kilogram - 6 participants at 0.8 mg per kilogram - 7 participants at 1.0 mg per kilogram The group's average age was 52 years (range 27 to 66), and 24 participants (69%) were men. Most participants were White (30 participants, 86%), with 6 Asian participants (17%) and 1 Black participant (3%). Their mean weight was 79 kg (±14), with an average body-mass index of 27 (±4). At the start of the study, participants' average LDL cholesterol was **129 mg per deciliter (3.3 mmol per liter)** and average PCSK9 level was 455 μg per liter (±98) — levels well above recommended targets for high-risk patients. The participants fell into three clinical categories: - 20 participants (57%) had heterozygous familial hypercholesterolemia only - 9 participants (26%) had both heterozygous familial hypercholesterolemia and premature coronary artery disease - 6 participants (17%) had premature coronary artery disease alone In total, 29 participants (83%) had familial hypercholesterolemia. At baseline, 32 participants (91%) were taking a statin, including 25 (71%) on a high-intensity statin, and 15 (43%) were taking ezetimibe. The median follow-up duration was approximately 9 months, with individual last visits occurring between 28 days and 18 months after dosing. ## Safety Results: What Side Effects Occurred The safety results are the central finding of this phase 1 trial. **No dose-limiting toxic effects occurred, no participants withdrew, and there were no deaths.** All 35 participants received the full planned dose of VERVE-102. Any adverse event occurred in 26 participants (74%), but most were mild. **Infusion-related reactions** occurred in 7 participants (20%), and all were grade 1 or 2 (mild to moderate). The details: - Five participants had grade 1 reactions (2 in the 0.7-mg/kg group, 2 in the 1.0-mg/kg group, and 1 in the 0.8-mg/kg group) that resolved without any medical treatment. - Two participants had grade 2 reactions (1 in the 0.6-mg/kg group and 1 in the 0.7-mg/kg group) that were treated with paracetamol (acetaminophen) or antihistamines. - One grade 1 reaction in a participant who received 0.7 mg per kilogram led to a temporary interruption of the infusion of approximately 40 minutes. **Liver enzyme elevations:** Transient, asymptomatic elevations in alanine aminotransferase (ALT, a liver enzyme) appeared in the early days after infusion. Among the 35 participants, 3 had ALT levels that met or exceeded two times the upper limit of normal, peaking at 2.0, 2.2, and 2.4 times the upper limit. These participants were 1 person in the 0.7-mg/kg group and 2 in the 1.0-mg/kg group. In all three, ALT peaked on day 3 or 4 and dropped back below two times the upper limit of normal by day 8. No symptoms were associated with these elevations. **Serious adverse events:** One participant who received 0.45 mg per kilogram developed **grade 3 aspiration pneumonitis** (lung inflammation from inhaling stomach contents) about 2 weeks after the infusion. This participant had a history of gastroesophageal reflux disease (GERD) and a sliding hiatal hernia. They were hospitalized for evaluation and discharged the next day. The study investigator assessed this event as unrelated to VERVE-102. No adverse events higher than grade 3 occurred at any point in the study. Treatment-related adverse events of any kind occurred in 11 participants (31%). The only treatment-related events occurring in more than one participant were infusion-related reaction (7 participants, 20%) and fatigue (2 participants, 6%). ## Key Findings: Reductions in PCSK9 and LDL Cholesterol The therapy worked as intended, producing **dose-dependent reductions in both blood PCSK9 protein and LDL cholesterol** across all six dose groups. Results below are "time-averaged" values, meaning they reflect the average reduction measured from day 28 through each participant's last follow-up visit (calculated using the area under the curve). **Reductions in PCSK9 protein (measured in the blood):** - 0.3 mg/kg dose: mean reduction of **51%** (range, −73% to −30%) - 0.45 mg/kg dose: mean reduction of **59%** (range, −92% to −34%) - 0.6 mg/kg dose: mean reduction of **61%** (range, −84% to −38%) - 0.7 mg/kg dose: mean reduction of **64%** (range, −93% to −34%) - 0.8 mg/kg dose: mean reduction of **77%** (range, −87% to −66%) - 1.0 mg/kg dose: mean reduction of **88%** (range, −94% to −78%) **Reductions in LDL cholesterol:** - 0.3 mg/kg dose: mean reduction of **9%** (range, −26% to +26%) - 0.45 mg/kg dose: mean reduction of **44%** (range, −57% to −30%) - 0.6 mg/kg dose: mean reduction of **45%** (range, −54% to −34%) - 0.7 mg/kg dose: mean reduction of **33%** (range, −70% to −14%) - 0.8 mg/kg dose: mean reduction of **51%** (range, −86% to −16%) - 1.0 mg/kg dose: mean reduction of **62%**, with an absolute reduction of **78 mg per deciliter** To put that in context, if a patient's starting LDL cholesterol was 129 mg/dL (the average in this study), a 62% reduction would bring it to roughly 49 mg/dL — far below the guideline-recommended target for very high-risk patients. The absolute reduction of 78 mg/dL at the highest dose is more than double the 39 mg/dL (1.0 mmol/L) reduction that earlier statin trials associated with a 22% drop in major vascular events over 5 years. ## How Long Did the Effects Last? The reductions appeared to be durable throughout follow-up. At the time of this interim analysis, 15 participants had been followed for at least 1 year, and some had study visits as late as 18 months after their single infusion. In these participants, the LDL-lowering effect was maintained, and the time-averaged analysis confirmed that reductions measured after day 28 persisted without fading over time. This durability is the central goal of the therapy — one treatment designed to provide years of protection instead of daily pills or regular injections. ## Exploring the Dose Response The researchers explored two ways of analyzing the dose response: the weight-based dose (mg per kilogram) and the total absolute amount of RNA each participant received, which equals the dose multiplied by body weight. The total RNA dose correlated with the reduction in LDL cholesterol, with a Pearson correlation coefficient of **−0.68** (a strong negative correlation, meaning higher doses produced larger LDL reductions). This finding suggests that the effect depends on the total amount of therapy delivered, an important consideration for future dosing decisions in heavier and lighter patients. ## What This Means for Patients (Clinical Implications) The authors summarize the takeaway: a single infusion of VERVE-102 produced dose-dependent and sustained reductions in PCSK9 and LDL cholesterol, with a mean reduction of 88% and 62%, respectively, at the highest dose. Side effects were limited to mild-to-moderate infusion reactions and transient liver enzyme elevations below 2.5 times the upper limit of normal. Why does this matter for patients? Because the single biggest problem in cholesterol management today is not that the medications don't work — it's that people stop taking them. Rates of discontinuation run from 30% to 50% within a year across all treatment classes, including self-injected PCSK9 inhibitors. When patients stop, their cholesterol rises and their cardiovascular risk returns. A one-time therapy that durably lowers LDL could potentially eliminate the adherence problem altogether. The biology is also favorable. Human genetic evidence shows that people born with PCSK9 loss-of-function variants have lifelong low LDL and up to 88% lower lifetime risk of coronary artery disease — with no apparent adverse effects. VERVE-102 is designed to recreate, in adulthood, the same protective state that nature produces in these rare individuals. Because the edit is made in the liver at the DNA level, the effect should persist as long as the edited liver cells live, without requiring the patient to do anything after the infusion. The authors indicate the results support four key insights into this approach. The first insight relates to the GalNAc-lipid nanoparticle delivery system, which enabled targeting of the liver via both the asialoglycoprotein receptor and LDL receptor pathways. This delivery platform is foundational to the favorable safety and efficacy profile seen in the trial. The full discussion of these insights appears in the original article. If larger studies confirm these results, this approach could represent a fundamental shift in preventive cardiology — moving from chronic daily therapy to a single, durable intervention delivered early in a patient's disease course, when the potential lifetime benefit is greatest. ## Study Limitations: What This Trial Could Not Prove This was a small, early-phase study, and its results must be interpreted with appropriate caution: - **Small sample size:** Only 35 participants received the therapy, with as few as 4 people in some dose groups. Rare side effects cannot be detected at this scale. - **No control group:** The study was open-label with no placebo comparison, so the safety findings cannot be directly compared with untreated patients. - **Interim analysis:** The results are from a non-prespecified interim analysis, and no formal statistical testing was performed. The study is still enrolling toward its target of 85 participants. - **Short duration for safety:** Although some participants were followed for 18 months, long-term safety — including any effects on cancer risk, liver health, or unintended gene changes — requires many more years of observation in larger populations. - **Specific patient population:** Participants all had heterozygous familial hypercholesterolemia or premature coronary artery disease, and most were White. Results may differ in other groups, including people with higher baseline LDL from other causes. - **No outcomes measured:** This study measured cholesterol levels, not actual heart attacks, strokes, or deaths. Whether the LDL reduction translates into fewer cardiovascular events — and whether that benefit is comparable to naturally occurring PCSK9 variants — remains unproven. - **Curious variability:** Some response ranges were wide (for example, LDL changes ranged from +26% to −26% at the lowest dose), and the 0.7-mg/kg group had a smaller mean LDL reduction (33%) than the 0.6-mg/kg group (45%). This may reflect the small group sizes or biological variability, and it needs further study. - **The one serious event:** The case of aspiration pneumonitis in a participant with GERD underscores that careful participant selection and monitoring will matter in future trials. Importantly, VERVE-102 is not yet approved by any regulatory authority. It is an investigational therapy available only in clinical trials. ## Recommendations for Patients Now For patients living with familial hypercholesterolemia, premature heart disease, or otherwise elevated cholesterol, the practical takeaways from this study are: - **Keep taking your current medications.** Statins, ezetimibe, and PCSK9 inhibitors remain the standard of care with proven cardiovascular benefit. Do not stop or change any treatment based on this early research. - **Talk to your doctor about your LDL target.** If you have familial hypercholesterolemia or established heart disease, your risk is high, and guidelines recommend aggressive LDL lowering. Ask whether you are at your goal. - **Consider whether you are a candidate for ongoing trials.** Gene-editing therapies like VERVE-102 are in early clinical development. Patients interested in participating can ask their cardiologist or lipid specialist about trial sites and eligibility. The trial is registered at ClinicalTrials.gov under number NCT06164730. - **Do not wait for an "infusion cure" before acting on your risk.** The benefits of LDL lowering accrue over time, and every year of untreated high cholesterol matters. The most powerful protection available today begins with the treatment you start now and keep taking. ## Frequently Asked Questions ### What is VERVE-102 and how does it lower cholesterol? VERVE-102 is an investigational one-time gene-editing therapy given by intravenous infusion. It uses base editing to make a single chemical change in the PCSK9 gene in liver cells, reducing production of PCSK9 protein. This allows the liver to remove more LDL cholesterol from the blood. It is not yet approved anywhere. ### Who could join this VERVE-102 clinical trial? Adults aged 18 to 70 with heterozygous familial hypercholesterolemia or premature coronary artery disease, and fasting LDL cholesterol of at least 70 mg/dL despite maximum tolerated oral therapy, could participate. People with uncontrolled high blood pressure, poorly controlled type 2 diabetes, or ongoing PCSK9 inhibitor use were excluded. ### What side effects did participants experience in the VERVE-102 trial? Most side effects were mild to moderate. Infusion-related reactions occurred in 20% of the 35 participants and usually resolved without treatment. Some had temporary, symptom-free liver enzyme elevations that peaked around day 3 or 4 and returned to normal by day 8. No dose-limiting toxic effects or deaths were reported. ### How much did VERVE-102 lower LDL cholesterol and PCSK9 levels? In this phase 1 trial, reductions were dose-dependent. At the highest dose tested, 1.0 mg per kilogram, the average LDL cholesterol reduction was 62%, corresponding to an absolute drop of 78 mg/dL. Blood PCSK9 protein fell by an average of 88% at that dose. ### How long did the cholesterol-lowering effect of VERVE-102 last? The effect appeared durable. At the time of the interim analysis, 15 participants had been followed for at least one year, and some had visits as late as 18 months after their single infusion. Their LDL reductions remained steady without fading, supporting the therapy's goal of one-time, lasting benefit. ### Is VERVE-102 approved for patients with high cholesterol? No. VERVE-102 is an investigational therapy available only in clinical trials and has not been approved by any regulatory authority. The trial is registered at ClinicalTrials.gov under number NCT06164730. Patients interested in gene-editing research should ask their cardiologist or lipid specialist about eligibility and trial sites. ### What should patients do now after learning about VERVE-102? Do not stop or change your current medications. Statins, ezetimibe, and PCSK9 inhibitors remain standard care with proven benefit. Talk to your doctor about whether you have reached your LDL target. If you have familial hypercholesterolemia or premature heart disease, ask about your risk and whether you might be a candidate for ongoing trials. ### Should I get a second opinion before considering the VERVE-102 gene-editing trial for my high cholesterol? For someone with familial hypercholesterolemia or premature heart disease, a second opinion makes sense before deciding whether to enroll in a gene-editing trial like VERVE-102. This therapy is investigational and not approved; it produced up to 62% LDL reduction but long-term safety and outcomes remain unproven. Your current statin, ezetimibe, or PCSK9 inhibitor remains standard care with proven benefit. A second opinion can confirm your LDL target, review your treatment plan, and clarify the risks and unknowns of experimental gene editing. Diagnostic Detectives Network provides independent expert second opinions. ## Source Information **Original article title:** In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia **Authors:** Scott B. Vafai, M.D., Jörg Täubel, M.D., Thomas Ashdown, M.B., Ch.B., Riyaz S. Patel, M.B., B.S., M.D., Sadaf Diamondali, M.B., B.S., Jaimini Cegla, M.B., B.S., Ph.D., Handrean Soran, M.D., Bilal Bashir, M.B., B.S., Alexander Abitbol, M.D., Daniel Gaudet, M.D., Ph.D., Alex Lauzière, M.D., Liam R. Brunham, M.D., Ph.D., David E. Newby, M.D., Ph.D., Stephen J. Nicholls, M.B., B.S., Ph.D., Russell S. Scott, M.B., Ch.B., Ph.D., Jane Kerr, M.B., Ch.B., M.P.H., Jean-Claude Tardif, M.D., Catherine Lunken, B.M., B.Ch., Steve E. Humphries, Ph.D., Verena Karsten, Ph.D., Patrick D. Tyler, M.D., Xinyan Zhang, Ph.D., Nidal Huniti, Ph.D., Patrick A. Flight, Ph.D., Chelsey L. Jensen, B.S., Rick Falzone, B.S., M.P.H., Joseph C. Biedenkapp, Ph.D., Troy Lister, Ph.D., Leslie E. Stolz, Ph.D., Amit V. Khera, M.D., and Sekar Kathiresan, M.D. **Journal:** The New England Journal of Medicine, 2026; volume 395, pages 648–659. Published May 25, 2026. **DOI:** 10.1056/NEJMoa2601283 **Funding:** Verve Therapeutics (a subsidiary of Eli Lilly). ClinicalTrials.gov number: NCT06164730. This patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and does not constitute medical advice. Always consult your healthcare provider about your individual treatment plan. --- Publisher: Diagnostic Detectives Network (https://diagnosticdetectives.com) — independent multi-expert medical second opinions, worldwide, private-pay. Author byline: Anton Titov, MD, PhD. Contact: https://diagnosticdetectives.com/pages/contact Canonical page: https://diagnosticdetectives.com/products/one-infusion-to-rewrite-a-cholesterol-gene-what-the-verve-102-base-editing-trial-means-for-patients